美国Corcept 
位于加州门洛帕克市的米非司酮的生产商Corcept制药公司

Corcept Therapeutics is a leader in the discovery and development of drugs that regulate the effects of cortisol.
There are many diseases in which modulating cortisol activity may benefit patients. Corcept’s scientific expertise surrounding the regulation of cortisol has led to the discovery of an extensive library of novel compounds that may ultimately address numerous important diseases.
Corcept’s drug Korlym™ (Mifepristone) 300 mg Tablets has been approved to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have diabetes mellitus type 2 or glucose intolerance and have failed surgery or are not candidates for surgery.